Topic: Depomed Inc.
(Reuters) - Shares of Depomed Inc fell as much as 29 percent to their lowest in a year, after the specialty pharmaceutical company said its experimental drug to treat menopausal hot flashes showed mixed results in a late-stage study.The trial data for ...
Depomed, Inc. (Nasdaq: DEPO) today announced presentations of clinical data of Breeze 1 and 2 at the North American Menopause Society (NAMS) Annual Meeting in Chicago, Illinois on October 8, 2010. Both Breeze 1 and 2 are Phase 3 trials that evaluated ...
Most notably, Pfizer (PFE) has completed data collection for it's 2186-patient study of Pristiq for the treatment of vasomotor symptoms, more commonly known as hot flashes. Wyeth, now part of Pfizer, began Pristiq's large trial in July of 2007, when the FDA ...
Depomed, Inc. (DEPO) Q1 2010 Earnings Call Transcript April 29, 2010 5:00 pm ET. With me today are Carl Pelzel, President and Chief Executive Officer of Depomed; Tammy Cameron, our Vice President, Finance; and Dr. Mike Sweeney, our Vice President, Research and ...
DEPO), a specialty pharmaceutical company, announced positive phase 3 trial results for the treatment of Post Herpetic Neuralgia ('PHN') with DM1796. Furthermore, it seems highly likely that DepoMed will implement certain tweaks to trial design to limit the two confounding factors that ...
DEPO) announced today top-line results from the BREEZE 1 and 2 Phase 3 clinical trials evaluating the safety and efficacy of SeradaTM, an investigational non-hormonal extended release formulation of gabapentin for the treatment of menopausal hot flashes.. All four co-primary endpoints of ...
From Around the Web
Video Gallery
-
PANL, WPRT, MAKO, LQDT, NUS - Stock ...
09/13/11 - It was another pleasant day on Wall ...2011-09-14 -
BSFT, DSCI, SFLY, TA -- Stock Charts ...
02/03/11 - There are still quite a few bullish ...2011-02-04 -
Pre-market Movers: January 19th, 2011
Equity futures are pointing lower with theDow Jones Industrial Average ...2011-01-19
